Abstract
Purpose: :
To assess the fixation stability in patients with exudative age-related macular degeneration (AMD) treated with intravitreal anti-VEGF injections. The 6 months results will be presented.
Methods: :
Fortynine treatment naïve patients (49 eyes) with exudative AMD were included. Patients were treated with either 1.25 mg intravitreal bevacizumab or 0.5 mg ranibizumab in one eye at baseline and were retreated every 6/4 weeks on an as needed basis. Ophthalmic outcome measures were pre- and post-injection fixation stability (Eye-Link System, Senso Motoric Instruments GmbH) performed at baseline, 3 and 6 months. Fixation stability was measured monocularly and binocularly by two head-born infrared cameras measuring horizontal and vertical movements of the eyes. These angular movements were transformed into linear distances at the retinal plane allowing an evaluation of the retinal area in degrees2 or arcminutes2 used for fixation. The mean value of 2 monocular recordings from each patient at each examination point was used for the analysis.
Results: :
The fixation stability was significantly improved from baseline to 6 months; mean (± SD) retinal area decreased from 6.0 (± 7.16) degrees2 at baseline to 4.0 (± 3.09) degrees2 at 6 months (p=0.043).
Conclusions: :
Patients with neovascular AMD are known to have an impaired central vision; however, few studies have examined the impact of this on their fixation stability. Our results indicate that after intravitreal anti-VEGF treatment the retinal area used for fixation is significantly decreased meaning the fixation stability improved.
Keywords: eye movements • age-related macular degeneration • vascular endothelial growth factor